Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone in Incurable Differentiated Thyroid Cancer
NCT00098852Phase 2Unknown
- Sponsor
- University of California, San Francisco
- Start
- Oct 2004
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rosiglitazone in differentiated thyroid cancer (DTC), sponsored by University of California, San Francisco. Primary endpoints: Complete Response at 1 year and Radioiodine uptake and thyroglobulin level at 1 year. Status: unknown.
02
Drugs
rosiglitazone
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT00098852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00098852.